Dendreon (DNDN) volatility of 65 near two-year lows
Dendreon (Nasdaq: DNDN) is recently up 17c to $27.95 in pre-open trading. On April 29 DNDN announced its Provenge drug prolonged the lives of advanced prostate-cancer patients by 4.1 months, raising expectations for the approval by the U.S. Food and Drug Administration. DNDN November option implied volatility is at 68, December is at 65; below its five-month average of 73, according to Track Data, suggesting decreasing price movement. Paul Foster
You May Also Be Interested In
- UPDATE: Jefferies Starts Dendreon (DNDN) at Underperform, Sees 35% Downside
- Arena Pharma (ARNA) Volatility Elevated, Shares Higher After Close of $70M Offering
- Jefferies Starts Dendreon (DNDN) at Underperform, Nektar (NKTR) at Buy
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
